← Scroll for more →
Financial Statements — BIOA
Balance Sheet
(in millions USD)| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 73.96 | 241.78 | 188.89 | 215.57 | 220.33 | 257.49 | 354.35 | 334.47 |
| Short-term Investments | 244.78 | 141.42 | 92.21 | 70.21 | 76.97 | 63.03 | -- | -- |
| Accounts Receivable | 0.63 | 0.71 | 0.77 | 0.52 | 0.60 | 0.36 | -- | -- |
| Total Current Assets | 330.31 | 391.86 | 286.79 | 290.83 | 301.70 | 324.81 | 357.10 | 336.47 |
| Property, Plant & Equipment | 1.21 | 1.12 | 0.96 | 0.97 | 0.97 | 0.93 | 0.59 | 0.54 |
| Total Non-current Assets* | 66.62 | 5.79 | 8.10 | 14.26 | 20.45 | 19.03 | 1.13 | 0.91 |
| Total Assets | 396.93 | 397.65 | 294.89 | 305.09 | 322.15 | 343.84 | 358.23 | 337.38 |
| Accounts Payable | 5.65 | 3.07 | 2.67 | 5.02 | 1.33 | 3.99 | 2.00 | 2.10 |
| Total Current Liabilities | 19.22 | 15.83 | 20.14 | 24.49 | 22.84 | 23.74 | 27.78 | 19.08 |
| Long-term Debt | -- | -- | 0.00 | 0.00 | 0.00 | 7.06 | 8.50 | 9.94 |
| Total Non-current Liabilities* | 2.80 | 2.71 | 2.70 | 3.13 | 4.53 | 6.94 | 7.33 | 4.55 |
| Total Liabilities | 22.02 | 18.53 | 22.84 | 27.63 | 27.37 | 30.67 | 35.11 | 23.63 |
| Retained Earnings | (381.77) | (355.67) | (333.42) | (307.47) | (287.30) | (265.74) | (252.81) | (231.68) |
| Total Stockholder Equity | 374.91 | 379.12 | 272.05 | 277.46 | 294.78 | 313.17 | 323.13 | 313.75 |
← Scroll for more columns →
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2.45 | 2.77 | 3.08 | 2.05 | 2.41 | 1.45 | 0.00 | 0.00 |
| Research & Development | 24.37 | 20.41 | 24.50 | 18.51 | 19.84 | 11.11 | 19.23 | 20.02 |
| Selling, General & Admin | 7.42 | 7.74 | 7.00 | 6.68 | 7.34 | 6.79 | 6.14 | 4.73 |
| Total Operating Expenses | 31.78 | 28.15 | 31.50 | 25.19 | 27.18 | 17.90 | 25.36 | 24.75 |
| Operating Income | (29.33) | (25.37) | (28.42) | (23.14) | (24.77) | (16.45) | (25.36) | (24.75) |
| Net Income | (26.10) | (22.25) | (25.94) | (20.17) | (21.56) | (12.93) | (21.13) | (23.41) |
| Basic EPS | (0.58) | (0.52) | (0.72) | (0.56) | (0.60) | (0.36) | 15.13 | (6.70) |
| Diluted EPS | (0.58) | (0.52) | (0.72) | (0.56) | (0.60) | (0.36) | 15.13 | (6.70) |
← Scroll for more columns →
Cash Flow Statement
(in millions USD)| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | (19.26) | (24.05) | (28.25) | (16.04) | (19.97) | (17.36) | (5.14) | (46.38) |
| Capital Expenditures | 0.33 | 0.03 | 0.11 | 0.02 | 0.16 | 0.43 | 0.03 | 0.34 |
| Free Cash Flow* | (19.59) | (24.07) | (28.36) | (16.07) | (20.13) | (17.79) | (5.16) | (46.72) |
| Investing Cash Flow | (164.51) | (46.75) | (14.43) | 12.84 | (15.64) | (77.99) | (0.03) | (0.34) |
| Financing Cash Flow | 15.97 | 123.72 | 16.01 | (1.54) | (1.50) | (1.50) | 24.90 | 356.30 |
← Scroll for more columns →
* Derived from reported values